Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

Examining the critical supply chain for the clinical trial process

With a commitment to process optimization, training, and audits to enhance their operations, CROs can ensure the integrity of medications throughout the trial process.

Examining the critical supply

[Adobe Stock – SneakyPeakPoints/peopleimages.com]

Profile photo of Guy Yehiav

President · SmartSense by Digi

In the U.S., there are over 165,000 clinical trials each year. With rising pressure to be first to market and accelerate the speed of research to mitigate growing costs, ensuring the integrity of samples and experimental medications throughout the research lifecycle is increasingly critical. 

Managing compliance-required condition data at each point of a clinical sample’s physical journey is a complicated endeavor, demanding command and control of cold chain operations, staff-executed corrective actions, and the availability of in-depth data analysis. Leaders of contract research organizations (CROs) must have proper technology resources and oversight frameworks in place to ensure patient safety and maintain transparency and trust with sponsors.  

Inflationary cost pressures are adding to the burden on research processes, but the same amount of new drugs are hitting the market annually as in the past. Given the rising costs, proper execution in the realms of condition monitoring, quality control, and data oversight is essential for controlling costs and mitigating potential risks of trial failure or delay. 

Destruction and loss of clinical samples destroy investments going back multiple years, not to mention the delay in solutions for patients. And for CROs, the pressure to be able to provide verified condition data comes from both regulatory bodies and the clients sponsoring the research.  

THE CRITICALITY OF CLINICAL TRIALS  

Clinical trials are an essential step in bringing new medications and treatments to the market. These trials are carefully designed to test the safety and efficacy of potential life-saving drugs and procedures. However, what many enterprise leaders may not realize is that there is an intricate and complex supply chain that is necessary to support these critical trials.  

Two factors stand out as crucial components of the supply chain for medical research—the need for specialized inventory management and the importance of maintaining specific environmental conditions. Having the proper equipment and tools on hand is paramount when it comes to conducting clinical trials. A stock of examination, assessment, and procedural tools must always be available to maintain the essential functions and ensure the processes for patient monitoring, data collection, and analysis are not interrupted.  

Much like the wind tunnel testing conducted with airplane models, clinical trial medications undergo specific environmental condition monitoring to ensure their effectiveness. This testing involves subjecting the medications to varying temperatures and humidity levels to simulate real-world conditions.

For example, in the case of the COVID-19 vaccine development, time and temperature standards were tested and established to provide requirements for different holding conditions—freezer, deep freezer, refrigerator, and room temperature environments. With this knowledge solidified, organizations throughout the cold chain are empowered to create the proper storage and handling conditions for medications and vaccines to maintain their efficacy.  

In addition to environmental condition control, CROs must also consider the impact of gases and oxygen exposure on the stability of medications. Exposure to oxygen can degrade certain medications, rendering them ineffective. This necessitates the use of protective packaging and storage solutions to minimize the risk of contamination.  

NAVIGATING COSTS OF SMALL BATCHES  

One of the main challenges faced in the clinical trial process is the need to produce small batches of experimental medications before full approval is granted. This involves careful attention to detail in terms of ingredient quantities, temperature control, and humidity levels to maintain the integrity of the batch.  

Moreover, the handling of these small batches of medications comes with a high cost due to the specialized nature of the supply chain and the lack of advantages from economies of scale. CRO leaders must regularly assess and improve their current inventory management practices. Here are a few ways to do so:

1. Adjust standard operating procedures. Adjust SOPs for monitoring critical environmental factors to ensure they are standing with up-to-date best practices and emerging evidence-based research.

2. Optimize set point temperature for any assets. If too low or too high, multiple alarms will create false positives that could receive declining attention from staff. 

3. Review employee certification levels and training gaps. Offer training and ongoing professional education opportunities to staff members to empower continuous improvement and expertise levels within your labor force. 

4. Measure execution rates for corrective actions. Then, identify areas of deviation from established standards. 

5. Appraise physical surroundings. Clean rooms, negative pressure rooms, and existing equipment should be assessed for quality and safety to ensure the integrity of the research process. 

OPTIMIZING OPERATIONS AND ENSURING INTEGRITY 

There is significant complexity associated with maintaining the integrity of medications throughout the clinical trial process. Without the proper oversight of the supply chain and environmental conditions, the entire clinical trial could be jeopardized, leading to wasted resources and delays in the development of new treatments. 

With a commitment to process optimization, team training, and internal audits to enhance their operations, CROs can ensure the integrity of medications throughout the trial process. With these strategies in place, leaders can help advance medical science, bring new treatments to market, and improve patient outcomes.